Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

IPCA Laboratories Limited

NSE: IPCALABPharmaceuticals

Share price

₹1,938.40

-0.01% close of 8 Oct 2026

Market cap ₹48,460 CrP/E 35.3

Business score

How strong the business is, in one number. The parts behind it are in Pro.

72

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹48,460 Cr

P/E ratio

35.3

P/B ratio

6.1

ROCE

17.0%

ROE

15.7%

Dividend yield

0.3%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹2,009.6052-week low ₹1,268.70

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 10.6% over the past year, and 12.3% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 19.7% to 22.0% over the last four years.

Whether it grew faster than its sector

It grew 12.3% a year against a sector median of 13.1% — 0.7 percentage points slower.

Room to re-rate, or risk of de-rating

At 35.3× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 37.5×, the 33rd percentile of its own range.

Whether growth justifies the valuation

Priced at 1.0 times its growth rate, on earnings growth of 37%.

Profit growthPrice per ₹1 profitPer 1% growth
IPCA Laboratories Limited — this one37%/yr35.3×₹0.95
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 50 of 130 on returns, 57 of 127 on growth, 50 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 17% on capital, ahead of 62% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹5070 crore of cash from the business, spent ₹2756 crore on plant and equipment, and returned ₹656 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 132 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 102 days for its cash to waiting 109 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Raised the full-year growth and margin targets after a 21% revenue quarter

Announced 13 Aug 2026 · Consolidated · Unaudited

Revenue

₹2,788 Cr

Revenue vs last year

+20.7%

Revenue vs last quarter

+16.8%

Net profit

₹424 Cr

Profit vs last year

+82.1%

Profit vs last quarter

+38.2%

Net margin

15.2%

EPS

₹15.84

Earnings call transcript · 14 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹48,460 Cr
Prev close
₹1,938.40
52w High
₹2,038
52w Low
₹1,252
Enterprise value
₹48,071 Cr
Beta
0.4
Price CAGR 1y
43.0%
Price CAGR 3y
27.0%
Price CAGR 5y
11.0%
Price CAGR 10y
20.0%

Ratios

Return on assets
9.6%
PEG ratio
1.0
P/E ratio
35.3
P/B ratio
6.1
EV / EBITDA
21.5
Industry P/E
38.0
ROCE
17.0%
ROCE 5y average
15.2%
ROE
15.7%
Debt / Equity
0.1
Interest coverage
20.9
Dividend yield
0.3%
ROE 3y average
13.0%
ROE last year
16.0%

Annual P&L

Annual revenue
₹9,599 Cr
Annual profit
₹1,184 Cr
Operating margin
21.0%
Net profit margin
12.3%
EBITDA margin
20.7%
Sales growth 3y
15.7%
Sales growth 5y
12.2%
Profit growth 3y
37.0%
Profit growth 5y
1.0%
EPS
₹45.0
Sales growth TTM
11.0%
Profit growth TTM
54.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹2,788 Cr
Profit latest quarter
₹424 Cr
YoY quarterly sales growth
20.8%
YoY quarterly profit growth
82.0%
OPM latest quarter
24.0%

Balance Sheet

Book Value
₹323
Face Value
₹1.0
Total debt
₹809 Cr
Total cash
₹565 Cr
Borrowings
₹809 Cr
Reserves / Equity
321.5

Cash Flow

Operating cash flow
₹1,142 Cr
Free cash flow
₹493 Cr
FCF yield
0.9%
Net cash flow
₹142 Cr

Shareholding

Promoter holding
44.7%
FII holding
10.7%
DII holding
37.0%
Public holding
7.2%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Ipca Labs.1,938.5035.849,1810.31424.372.32,788.120.817.0
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,5852,0342,0532,0332,0932,3552,2452,2472,3092,5572,3932,3882,788
Expenses1,2781,6731,7221,7111,7001,9131,7821,8181,8922,0121,8591,9052,119
Material Cost660617570564593638
Change in Inventories-39-5285-36-5019
Purchases of Stock-in-Trade87127127130149141
Employee Cost501543538546533602
Other Expenses609658692655680720
Operating Profit308361331322393441463429416545533484670
OPM %19181616191921191821222024
Other Income45-191-118212620-17933-30384825
Exceptional items (within Other Income)-2050-5818-460
Interest31443329242317221920182012
Depreciation6990100989910098100100103108107111
Profit before tax25222528977290345368128331392446404572
Tax %34392396312925492928182426
Net Profit164136221119924627664233281364307424
EPS in Rs6.425.727.092.357.589.059.782.679.1911131216
Diluted EPS in Rs2.679.1911131216

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,1442,8673,1563,2583,7464,6195,3955,7976,2047,6628,9409,64610,126
Expenses2,6042,5732,7052,8033,0513,7153,8434,4725,2726,3387,1667,6097,894
Material Cost2,2772,344
Change in Inventories-46-54
Purchases of Stock-in-Trade548533
Employee Cost1,9842,160
Other Expenses2,4512,685
Operating Profit5412944514556959041,5521,3259321,3241,7311,9902,232
OPM %17101414192029231517192122
Other Income322111415665595412317-1148081
Exceptional items (within Other Income)-205-86
Interest323527282220121148141887969
Depreciation180163173178182210209232262357398418429
Profit before tax3611172622915467391,3891,1367458431,1311,5731,814
Tax %281826181918172034373024
Net Profit254931952394426041,1418904795237851,1841,375
EPS in Rs103.697.719.49182445351922294552
Diluted EPS in Rs2945
Dividend Payout %50659109112219140

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
13%
5 years
12%
3 years
16%
TTM
11%

Compounded profit growth

10 years
30%
5 years
1%
3 years
37%
TTM
54%

Stock price CAGR

10 years
20%
5 years
11%
3 years
27%
1 year
43%

Return on equity

10 years
14%
5 years
13%
3 years
13%
Last year
16%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital252525252525252525252525
Reserves2,1832,2342,4302,6633,0973,6024,6765,4675,8176,3076,9238,038
Borrowings9358677166284655012658071,4811,4381,363809
Other Liabilities6697657887999611,1301,0991,3381,3003,3263,4323,477
Minority Interest1,4401,460
Total Liabilities3,8123,8923,9604,1164,5495,2586,0667,6378,62311,09711,74412,350
Fixed Assets1,8002,0141,9831,9531,9402,0592,0722,4182,7514,5544,2674,627
CWIP267129957366133235306140343622773
Investments162613687120310505989626862980844
Other Assets1,7291,7231,7462,0032,4222,7563,2543,9245,1055,3395,8756,106
Total Assets3,8123,8923,9604,1164,5495,2586,0667,6378,62311,09711,76112,370

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4687092823415015701,0908568069451,3211,142
Cash from Investing Activity-689-218-149-135-165-509-521-851-725-1,215-870-247
Cash from Financing Activity251-462-159-130-183-137-306427507-553-283-754
Net Cash Flow2929-2675153-76264432588-823169142
Free Cash Flow-207463147206322277731380347543551493

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days415758676671555758807777
Inventory Days293289290286316294337337276350336353
Days Payable9714513013715413514010183110111122
Cash Conversion Cycle237200218216228229251293251321302308
Working Capital Days68617480888810310271111101109
ROCE %1459101619312011131517

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters464646464645454545454545
FIIs9.861011111111111110111111
DIIs353434333435363636373737
Government0.320.320.320.320.320.320.320.320.320.320.320.32
Public8.808.938.829.078.648.538.458.418.097.337.217.19
No. of Shareholders95,93082,80981,16584,75382,97590,18988,30685,58282,87077,67382,18482,060

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +44.7% (₹1,339.50 → ₹1,938.40)Brick size ₹54.64 (fixed)Bricks 23
₹1,400₹1,600₹1,800₹1,938Nov '25Apr '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹1,938.40 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

own market share %

2.08pct

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-389inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

42,63,074inr

2026-03-31

News

News and filings about IPCA Laboratories Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Packing materials
  • Power and fuel
  • Raw materials for APIs and formulations

Products made by

Depends on the price of

  • fuel

Buys from

Sells to

  • Bayer Pakistan Pvt Ltd · antimalarial API / formulations
  • United States Strategic National Stockpile · hydroxychloroquine sulphate / chloroquine phosphate API + tablets

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE571A01038

Plants

  • Athal formulation plant
  • Chhatrapati Sambhajinagar (Aurangabad) API plant
  • Dehradun formulation plant (Unit I & II)
  • Dewas API plant
  • Indore API plant
  • Jorethang formulation plant
  • Kandla formulation plant
  • Mahad intermediates plant
  • Nandesari hormones plant
  • Piparia formulation plant
  • Pithampur formulation plant
  • Ranu (Baroda) API plant
  • Ratlam API plant
  • Ratlam formulation plant
  • SEZ Indore formulation plant
  • Tarapur API plant

News impact

Big market events that reach IPCA Laboratories Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

7 Aug 2026unspecified₹6
5 Aug 2025unspecified₹2
27 Nov 2024interim₹2
6 Aug 2024unspecified₹2
22 Nov 2023interim₹2
22 Nov 2022interim₹4
10 Jan 2022split₹0
22 Nov 2021interim₹8

Splits, bonuses & buybacks

  • daily-prices repair: 8 rows from NSE's archive (replace 1, delete 0, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.